<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Rifamycins: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i199.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i199.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i199.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i127.htm">Antibacterials</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i198.htm" title="Previous: Ofloxacin">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i200.htm" title="Next: Rifabutin">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i199">Rifamycins</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Rifamycins</b>
          has the following interaction information:
        </p><div>Interactions do not apply to rifaximin</div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i168.htm" name="_168">Clarithromycin</a></td><td> rifamycins reduce plasma concentration of clarithromycin </td><td></td></tr><tr><td><a href="41001i484.htm" name="_484">Corticosteroids</a></td><td class="cBV"><b> rifamycins accelerate metabolism of corticosteroids (reduced effect)</b></td><td>Interactions do not generally apply to corticosteroids used for topical action (including inhalation) unless specified</td></tr><tr><td><a href="41001i220.htm" name="_220">Coumarins</a></td><td class="cBV"><b> rifamycins accelerate metabolism of coumarins (reduced anticoagulant effect)</b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i161.htm" name="_161">Dapsone</a></td><td> rifamycins reduce plasma concentration of dapsone </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b> rifamycins accelerate metabolism of disopyramide (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i636.htm" name="_636">Oestrogens</a></td><td class="cBV"><b> rifamycins accelerate metabolism of oestrogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b> rifamycins accelerate metabolism of phenytoin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i664.htm" name="_664">Progestogens</a></td><td class="cBV"><b> rifamycins accelerate metabolism of progestogens (reduced contraceptive effect—see <a title="target-block: COCs interactions" href="4552.htm#_120026">section 7.3.1</a>)</b></td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="" href="4552.htm#_120026">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a title="" href="4572.htm#_4572.2">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a title="" href="4580.htm#_4580.4">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a title="" href="31947.htm#_31947.1">section 7.3.2.3</a>; hormonal emergency contraception, see also <a title="" href="130057.htm#_100043.3">section 7.3.5</a></td></tr><tr><td><a href="41001i268.htm" name="_268">Sulfonylureas</a></td><td class="cBV"><b> rifamycins possibly accelerate metabolism of sulfonylureas (reduced effect)</b></td><td></td></tr><tr><td><a href="41001i275.htm" name="_275">Tolbutamide</a></td><td class="cBV"><b> rifamycins accelerate metabolism of tolbutamide (reduced effect)</b></td><td></td></tr></tbody></table><p>Rifamycins belongs to <b>Antibacterials</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>

<tr><td><a href="41001i1058.htm">Typhoid Vaccine (oral)</a></td><td> antibacterials inactivate oral typhoid vaccine—see under Typhoid vaccines, <a title="monograph-family: Typhoid vaccines" href="6528.htm#_6528">section 14.4</a></td><td></td></tr></tbody></table><p><b>Rifabutin</b> belongs to
      <b>Rifamycins</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



























<tr><td><a href="41001i300.htm">Antifungals, Triazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin possibly increased by triazoles (increased risk of uveitis—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> rifabutin possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by atazanavir (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i431.htm">Atovaquone</a></td><td>avoidance of concomitant  rifabutin advised by manufacturer of atovaquone (plasma concentration of both drugs reduced)</td><td></td></tr><tr><td><a href="41001i167.htm">Azithromycin</a></td><td class="cBV"><b>increased risk of side-effects including neutropenia when  rifabutin given with azithromycin </b></td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  rifabutin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b> rifabutin reduces plasma concentration of carbamazepine </b></td><td></td></tr><tr><td><a href="41001i168.htm">Clarithromycin</a></td><td class="cBV"><b>plasma concentration of   rifabutin increased by clarithromycin (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by darunavir (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td>plasma concentration of  rifabutin reduced by efavirenz—increase dose of rifabutin</td><td></td></tr><tr><td><a href="41001i169.htm">Erythromycin</a></td><td class="cBV"><b>plasma concentration of  rifabutin possibly increased by erythromycin (increased risk of toxicity—reduce rifabutin dose)</b></td><td>Interactions do not apply to small amounts of erythromycin used topically</td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td class="cBV"><b>plasma concentration of both drugs reduced when  rifabutin given with etravirine </b></td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by fluconazole (increased risk of uveitis—reduce rifabutin dose)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by fosamprenavir (reduce dose of rifabutin)</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by indinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b> rifabutin reduces plasma concentration of itraconazole—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  rifabutin advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by nelfinavir (halve dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td>plasma concentration of  rifabutin possibly increased by nevirapine </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by posaconazole (also plasma concentration of posaconazole reduced)</b></td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of   rifabutin increased by ritonavir (increased risk of toxicity—reduce rifabutin dose)</b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by saquinavir (also plasma concentration of saquinavir reduced)</b></td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> rifabutin reduces plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td> rifabutin possibly reduces plasma concentration of tacrolimus </td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>avoidance of  rifabutin advised by manufacturer of telaprevir </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by tipranavir (reduce dose of rifabutin)</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b>plasma concentration of  rifabutin increased by voriconazole , also rifabutin reduces plasma concentration of voriconazole (increase dose of voriconazole and also monitor for rifabutin toxicity)</b></td><td></td></tr></tbody></table><p><b>Rifampicin</b> belongs to
      <b>Rifamycins</b>
          and has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>






















































































































<tr><td><a href="41001i907.htm">Abacavir</a></td><td> rifampicin possibly reduces plasma concentration of abacavir </td><td></td></tr><tr><td><a href="41001i86.htm">Alfentanil</a></td><td> rifampicin accelerates metabolism of alfentanil (reduced effect)</td><td></td></tr><tr><td><a href="41001i1099.htm">Aliskiren</a></td><td> rifampicin reduces plasma concentration of aliskiren </td><td></td></tr><tr><td><a href="41001i110.htm">Antacids</a></td><td>absorption of  rifampicin reduced by antacids </td><td>Antacids should preferably not be taken at the same time as other drugs since they may impair absorption</td></tr><tr><td><a href="41001i1217.htm">Apixaban</a></td><td> rifampicin reduces plasma concentration of apixaban </td><td></td></tr><tr><td><a href="41001i1010.htm">Aprepitant</a></td><td> rifampicin reduces plasma concentration of aprepitant </td><td></td></tr><tr><td><a href="41001i1011.htm">Aripiprazole</a></td><td class="cBV"><b> rifampicin possibly reduces plasma concentration of aripiprazole—increase dose of aripiprazole</b></td><td></td></tr><tr><td><a href="41001i1005.htm">Atazanavir</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of atazanavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i601.htm">Atorvastatin</a></td><td> rifampicin possibly reduces plasma concentration of atorvastatin </td><td></td></tr><tr><td><a href="41001i431.htm">Atovaquone</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of atovaquone (and concentration of rifampicin increased)—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i405.htm">Benzodiazepines</a></td><td> rifampicin possibly accelerates metabolism of benzodiazepines (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i443.htm">Bisoprolol</a></td><td> rifampicin accelerates metabolism of bisoprolol (plasma concentration  significantly reduced)</td><td></td></tr><tr><td><a href="41001i1214.htm">Boceprevir</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of boceprevir (plasma concentration of boceprevir possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i943.htm">Bosentan</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of bosentan—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i427.htm">Buspirone</a></td><td> rifampicin possibly accelerates metabolism of buspirone </td><td></td></tr><tr><td><a href="41001i1204.htm">Cabazitaxel</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of cabazitaxel </b></td><td></td></tr><tr><td><a href="41001i445.htm">Carvedilol</a></td><td> rifampicin reduces plasma concentration of carvedilol </td><td></td></tr><tr><td><a href="41001i947.htm">Caspofungin</a></td><td> rifampicin initially increases and then reduces plasma concentration of caspofungin (consider increasing dose of caspofungin)</td><td></td></tr><tr><td><a href="41001i898.htm">Celecoxib</a></td><td> rifampicin reduces plasma concentration of celecoxib </td><td></td></tr><tr><td><a href="41001i446.htm">Celiprolol</a></td><td> rifampicin reduces plasma concentration of celiprolol </td><td></td></tr><tr><td><a href="41001i158.htm">Chloramphenicol</a></td><td> rifampicin accelerates metabolism of chloramphenicol (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i499.htm">Ciclosporin</a></td><td class="cBV"><b> rifampicin accelerates metabolism of ciclosporin (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td> rifampicin accelerates metabolism of cimetidine (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td> rifampicin possibly reduces plasma concentration of clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i88.htm">Codeine</a></td><td> rifampicin accelerates metabolism of codeine (reduced effect)</td><td></td></tr><tr><td><a href="41001i1120.htm">Dabigatran Etexilate</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of dabigatran etexilate—manufacturer of dabigatran etexilate advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1091.htm">Darunavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of darunavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1077.htm">Dasatinib</a></td><td class="cBV"><b> rifampicin accelerates metabolism of dasatinib (reduced plasma  concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i1072.htm">Deferasirox</a></td><td> rifampicin reduces plasma concentration of deferasirox </td><td></td></tr><tr><td><a href="41001i412.htm">Diazepam</a></td><td> rifampicin accelerates metabolism of diazepam (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i64.htm">Diclofenac</a></td><td> rifampicin reduces plasma concentration of diclofenac </td><td></td></tr><tr><td><a href="41001i480.htm">Digoxin</a></td><td> rifampicin possibly reduces plasma concentration of digoxin </td><td></td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td class="cBV"><b> rifampicin accelerates metabolism of diltiazem (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i212.htm">Doxycycline</a></td><td> rifampicin reduces plasma concentration of doxycycline—consider increasing dose of doxycycline</td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of dronedarone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i874.htm">Efavirenz</a></td><td> rifampicin reduces plasma concentration of efavirenz—increase dose of efavirenz</td><td></td></tr><tr><td><a href="41001i1025.htm">Eplerenone</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of eplerenone—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1205.htm">Eribulin</a></td><td> rifampicin possibly reduces plasma concentration of eribulin </td><td></td></tr><tr><td><a href="41001i1048.htm">Erlotinib</a></td><td> rifampicin accelerates metabolism of erlotinib (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i960.htm">Etoricoxib</a></td><td> rifampicin reduces plasma concentration of etoricoxib </td><td></td></tr><tr><td><a href="41001i1135.htm">Etravirine</a></td><td>avoidance of  rifampicin advised by manufacturer of etravirine </td><td></td></tr><tr><td><a href="41001i1169.htm">Everolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of everolimus </b></td><td></td></tr><tr><td><a href="41001i1047.htm">Exemestane</a></td><td> rifampicin possibly reduces plasma concentration of exemestane </td><td></td></tr><tr><td><a href="41001i95.htm">Fentanyl</a></td><td> rifampicin accelerates metabolism of fentanyl (reduced effect)</td><td></td></tr><tr><td><a href="41001i1119.htm">Fesoterodine</a></td><td> rifampicin reduces plasma concentration of active metabolite of fesoterodine </td><td></td></tr><tr><td><a href="41001i308.htm">Fexofenadine</a></td><td> rifampicin possibly reduces effects of fexofenadine </td><td></td></tr><tr><td><a href="41001i301.htm">Fluconazole</a></td><td class="cBV"><b> rifampicin accelerates metabolism of fluconazole (reduced plasma concentration)</b></td><td>In general, fluconazole interactions relate to multiple-dose treatment</td></tr><tr><td><a href="41001i603.htm">Fluvastatin</a></td><td> rifampicin accelerates metabolism of fluvastatin (reduced effect)</td><td></td></tr><tr><td><a href="41001i1019.htm">Fosamprenavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of fosamprenavir—avoid concomitant use</b></td><td>Fosamprenavir is a prodrug of amprenavir</td></tr><tr><td><a href="41001i1170.htm">Gefitinib</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of gefitinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i387.htm">Haloperidol</a></td><td class="cBV"><b> rifampicin accelerates metabolism of haloperidol (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i933.htm">Imatinib</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of imatinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i870.htm">Imidapril</a></td><td> rifampicin reduces plasma concentration of active metabolite of imidapril (reduced antihypertensive effect)</td><td></td></tr><tr><td><a href="41001i398.htm">Indinavir</a></td><td class="cBV"><b> rifampicin accelerates metabolism of indinavir (reduced plasma  concentration—avoid concomitant use)</b></td><td></td></tr><tr><td><a href="41001i472.htm">Isradipine</a></td><td class="cBV"><b> rifampicin possibly accelerates metabolism of isradipine (possible significantly reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i302.htm">Itraconazole</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of itraconazole—manufacturer of itraconazole advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i298.htm">Ketoconazole</a></td><td class="cBV"><b> rifampicin accelerates metabolism of ketoconazole (reduced plasma concentration), also plasma concentration of rifampicin may be reduced by ketoconazole</b></td><td></td></tr><tr><td><a href="41001i283.htm">Lamotrigine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of lamotrigine </b></td><td></td></tr><tr><td><a href="41001i1128.htm">Lapatinib</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of lapatinib </b></td><td></td></tr><tr><td><a href="41001i891.htm">Leflunomide</a></td><td> rifampicin possibly increases plasma concentration of active metabolite of leflunomide </td><td>Increased risk of toxicity with other haematotoxic and hepatotoxic drugs</td></tr><tr><td><a href="41001i738.htm">Levothyroxine</a></td><td> rifampicin accelerates metabolism of levothyroxine (may increase requirements for levothyroxine in hypothyroidism)</td><td></td></tr><tr><td><a href="41001i1210.htm">Linagliptin</a></td><td> rifampicin possibly reduces effects of linagliptin </td><td></td></tr><tr><td><a href="41001i917.htm">Linezolid</a></td><td> rifampicin reduces plasma concentration of linezolid (possible therapeutic failure of linezolid)</td><td>Linezolid is a reversible, non-selective MAO inhibitor—see interactions of MAOIs</td></tr><tr><td><a href="41001i922.htm">Lopinavir</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of lopinavir—avoid concomitant use</b></td><td>In combination with ritonavir as <i>Kaletra</i>® (ritonavir is present to inhibit lopinavir metabolism and increase plasma-lopinavir concentration)—see also Ritonavir</td></tr><tr><td><a href="41001i108.htm">Losartan</a></td><td> rifampicin reduces plasma concentration of losartan and its active metabolite</td><td></td></tr><tr><td><a href="41001i1107.htm">Maraviroc</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of maraviroc—consider increasing dose of maraviroc</b></td><td></td></tr><tr><td><a href="41001i337.htm">Mefloquine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of mefloquine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i97.htm">Methadone</a></td><td> rifampicin accelerates metabolism of methadone (reduced effect)</td><td></td></tr><tr><td><a href="41001i451.htm">Metoprolol</a></td><td> rifampicin reduces plasma concentration of metoprolol </td><td></td></tr><tr><td><a href="41001i98.htm">Morphine</a></td><td> rifampicin accelerates metabolism of morphine (reduced effect)</td><td></td></tr><tr><td><a href="41001i520.htm">Mycophenolate</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of active metabolite of mycophenolate </b></td><td></td></tr><tr><td><a href="41001i920.htm">Nateglinide</a></td><td> rifampicin reduces plasma concentration of nateglinide </td><td></td></tr><tr><td><a href="41001i842.htm">Nelfinavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of nelfinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i843.htm">Nevirapine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of nevirapine—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i474.htm">Nicardipine</a></td><td class="cBV"><b> rifampicin possibly accelerates metabolism of nicardipine (possible significantly reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i475.htm">Nifedipine</a></td><td class="cBV"><b> rifampicin accelerates metabolism of nifedipine (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i1118.htm">Nilotinib</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of nilotinib—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i476.htm">Nimodipine</a></td><td class="cBV"><b> rifampicin accelerates metabolism of nimodipine (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i1045.htm">Ondansetron</a></td><td> rifampicin accelerates metabolism of ondansetron (reduced effect)</td><td></td></tr><tr><td><a href="41001i901.htm">Oxycodone</a></td><td> rifampicin possibly accelerates metabolism of oxycodone </td><td></td></tr><tr><td><a href="41001i1186.htm">Pazopanib</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of pazopanib </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td>plasma concentration of  rifampicin possibly reduced by phenobarbital </td><td></td></tr><tr><td><a href="41001i1060.htm">Posaconazole</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of posaconazole </b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b> rifampicin accelerates metabolism of propafenone (reduced effect)</b></td><td></td></tr><tr><td><a href="41001i793.htm">Propranolol</a></td><td> rifampicin accelerates metabolism of propranolol (plasma concentration  significantly reduced)</td><td></td></tr><tr><td><a href="41001i341.htm">Quinine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of quinine </b></td><td></td></tr><tr><td><a href="41001i1111.htm">Raltegravir</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of raltegravir—consider increasing dose of raltegravir</b></td><td></td></tr><tr><td><a href="41001i1147.htm">Ranolazine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of ranolazine—manufacturer of ranolazine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i855.htm">Repaglinide</a></td><td> rifampicin possibly antagonises hypoglycaemic effect of repaglinide </td><td></td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td> rifampicin possibly reduces plasma concentration of ritonavir </td><td></td></tr><tr><td><a href="41001i1136.htm">Rivaroxaban</a></td><td> rifampicin reduces plasma concentration of rivaroxaban </td><td></td></tr><tr><td><a href="41001i1190.htm">Roflumilast</a></td><td> rifampicin reduces plasma concentration of roflumilast—consider increasing dose of roflumilast</td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b> rifampicin significantly reduces plasma concentration of saquinavir , also risk of hepatotoxicity—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i605.htm">Simvastatin</a></td><td> rifampicin possibly reduces plasma concentration of simvastatin </td><td></td></tr><tr><td><a href="41001i921.htm">Sirolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of sirolimus—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1074.htm">Sorafenib</a></td><td> rifampicin reduces plasma concentration of sorafenib </td><td></td></tr><tr><td><a href="41001i1075.htm">Sunitinib</a></td><td> rifampicin accelerates metabolism of sunitinib (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i730.htm">Tacrolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of tacrolimus </b></td><td>Interactions do not generally apply to tacrolimus used topically; risk of facial flushing and skin irritation with alcohol consumption (<a title="monograph: TACROLIMUS" href="119635.htm#_119635">see section 13.5.3</a>) does not apply to tacrolimus taken systemically</td></tr><tr><td><a href="41001i945.htm">Tadalafil</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of tadalafil—manufacturer of tadalafil advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i581.htm">Tamoxifen</a></td><td> rifampicin accelerates metabolism of tamoxifen (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1216.htm">Telaprevir</a></td><td class="cBV"><b>plasma concentration of  rifampicin significantly reduced by telaprevir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i946.htm">Telithromycin</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of telithromycin (avoid during and for 2 weeks after rifampicin)</b></td><td></td></tr><tr><td><a href="41001i1137.htm">Temsirolimus</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of active metabolite of temsirolimus—avoid concomitant use</b></td><td>The main active metabolite of temsirolimus is sirolimus—<i>see also</i> interactions of sirolimus and consult product literature</td></tr><tr><td><a href="41001i292.htm">Terbinafine</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of terbinafine </b></td><td></td></tr><tr><td><a href="41001i734.htm">Theophylline</a></td><td> rifampicin accelerates metabolism of theophylline (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i737.htm">Tibolone</a></td><td> rifampicin accelerates metabolism of tibolone (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i1203.htm">Ticagrelor</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of ticagrelor </b></td><td></td></tr><tr><td><a href="41001i1055.htm">Tipranavir</a></td><td class="cBV"><b> rifampicin possibly reduces plasma concentration of tipranavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i1158.htm">Tolvaptan</a></td><td> rifampicin reduces plasma concentration of tolvaptan </td><td></td></tr><tr><td><a href="41001i217.htm">Trimethoprim</a></td><td> rifampicin possibly reduces plasma concentration of trimethoprim </td><td></td></tr><tr><td><a href="41001i1163.htm">Ulipristal</a></td><td class="cBV"><b>avoidance of  rifampicin advised by manufacturer of ulipristal (contraceptive effect of ulipristal possibly reduced)</b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td class="cBV"><b> rifampicin accelerates metabolism of verapamil (plasma concentration  significantly reduced)</b></td><td></td></tr><tr><td><a href="41001i1181.htm">Vinflunine</a></td><td class="cBV"><b> rifampicin possibly reduces plasma concentration of vinflunine—manufacturer of vinflunine advises avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i948.htm">Voriconazole</a></td><td class="cBV"><b> rifampicin reduces plasma concentration of voriconazole—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i904.htm">Zaleplon</a></td><td> rifampicin accelerates metabolism of zaleplon (reduced plasma concentration)</td><td></td></tr><tr><td><a href="41001i403.htm">Zidovudine</a></td><td>avoidance of  rifampicin advised by manufacturer of zidovudine </td><td>Increased risk of toxicity with nephrotoxic and myelosuppressive drugs—for further details consult product literature</td></tr><tr><td><a href="41001i425.htm">Zolpidem</a></td><td> rifampicin accelerates metabolism of zolpidem (reduced plasma concentration and reduced effect)</td><td></td></tr><tr><td><a href="41001i426.htm">Zopiclone</a></td><td> rifampicin significantly reduces plasma concentration of zopiclone </td><td></td></tr></tbody></table></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="41001i200.htm" title="Rifabutin">Rifabutin</a></li><li><a href="41001i201.htm" title="Rifampicin">Rifampicin</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i198.htm">Previous: Ofloxacin</a> | <a class="top" href="41001i199.htm#">Top</a> | <a accesskey="]" href="41001i200.htm">Next: Rifabutin</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>